The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: Where does it fit?

Research output: Contribution to journalArticleAcademicpeer-review

53 Citations (Scopus)


Bevacizumab is approved for the treatment of colorectal cancer, breast cancer, non-small cell lung cancer and renal cell cancer. Before embracing this expensive agent for many other indications, it remains critical to be aware of the evidence upon which oncologists base their day-to-day clinical practice. In this review, we address the results of clinical studies upon which bevacizumab's current use is based and discuss some future perspectives. (C) 2008 Elsevier Ltd. All rights reserved.
Original languageUndefined/Unknown
Pages (from-to)2350-2356
Number of pages7
JournalEuropean Journal of Cancer
Issue number16
Publication statusPublished - 2008

Cite this